Data on Non-Small Cell Lung Cancer Discussed by Researchers at University of Electronic Science and Technology of China [Randomized Trial of First-line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic...].
In: Clinical Trials Week, 2024-03-26, S. 228-228
serialPeriodical
Zugriff:
A recent study conducted by researchers at the University of Electronic Science and Technology of China explored the effectiveness of adding radiotherapy (RT) to systemic therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). The study found that the addition of upfront local therapy using RT significantly improved progression-free survival (PFS) and overall survival (OS) compared to treatment with a first-line tyrosine kinase inhibitor (TKI) alone. The trial enrolled 133 patients and concluded that RT was beneficial for EGFR-mutated NSCLC. The study was funded by various organizations and has been peer-reviewed. [Extracted from the article]
Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Data on Non-Small Cell Lung Cancer Discussed by Researchers at University of Electronic Science and Technology of China [Randomized Trial of First-line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic...].
|
---|---|
Zeitschrift: | Clinical Trials Week, 2024-03-26, S. 228-228 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6772 (print) |
Schlagwort: |
|
Sonstiges: |
|